Company News: Bristol-Myers Squibb, Pfizer, Xanodyne Pharmaceuticals and Human Genome Sciences

Share this article:
Bristol Myers-Squibb and Pfizer ended a phase III clinical trial of anticoagulant apixaban in patients with acute coronary syndrome. In an announcement, BMS said it remains committed to developing apixaban in other populations and hinted that a rolling NDA for approval of apixiban for stroke in atrial fibrillation is under way. Apixaban is also in phase III trials for VTE prevention.

FDA's Oncologic Drugs Advisory Committee postponed a Dec. 2 meeting to review BMS cancer drug ipilimumab, trade name Yervoy. According to a source at FDA, a new ad-com date has not been set. BMS submitted a BLA for the treatment of adults with advanced melanoma to the FDA in August, and the original PDUFA date was set for December 25, 2010.

Xanodyne Pharmaceuticals said it is voluntarily pulling its Darvon, Darvon-N and Darvocet-N painkillers from the US market as part of a market-wide withdrawal of all propoxyphene-containing products. FDA determined that the benefits of these products no longer outweigh potential risks, noted Xanodyne in a statement which specifically mentioned propoxyphene's effects on cardiac conduction. A number of other branded and generic versions of the 50-year-old drug are affected, it said.

An FDA advisory panel voted 13-2 to recommend approval of lupus drug Benlysta, which is being developed by Human Genome Sciences and GlaxoSmithKline. The FDA is set to make a final decision on the drug Dec. 9. The agency doesn't have to follow the advice of its advisory panels but generally does.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.